Sales Y/Y of Retrophin, Inc.
The annual revenue growth is calculated as is an arithmetic mean of a series of growth rates. For this specific metric the calculation takes into account a series of the last three annual growth rates. The average annual revenue growth is useful for determining trends but it can be misleading since only the differences between years are compared and not the starting and ending point (which can happen to be identical). As a result, compounded annual growth rate can be used for evaluating changing financial metrics.
Sales Y/Y of companies in the Health Care sector on NASDAQ compared to Retrophin, Inc.
About Retrophin, Inc.
Retrophin, Inc., a biopharmaceutical company, focuses on the development, acquisition, and commercialization of therapies for the treatment of serious or rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria. The company's product candidates consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis; Fosmetpantotenate, a novel small molecule that is in Phase III clinical trial to treat pantothenate kinase-associated neurodegeneration; Tetracosactide Zinc (RE-034), a synthetic hormone analog that is in preclinical stage; and Liquid Ursodeoxycholic Acid, a liquid formulation of ursodeoxycholic acid, which is in preclinical stage to treat primary biliary cholangitis. Retrophin, Inc. was founded in 2011 and is headquartered in San Diego, California.
- Retrophin, Inc., 3721 Valley Centre Drive, San Diego 92130, United States